Skip to Main Content

KMAP BULLETIN: Preferred Drug List Update – April 2026

Date: 04/01/26

KMAP GENERAL BULLETIN 26054 (PDF)

Effective with dates of service on or after April 1, 2026, the following medications will be Non-Preferred:

  • Alhemo® (Concizumab-mtci)
  • Hympavzi™ (Marstacimab-hncq)
  • Nypozi™ (filgrastim-txid)
  • Pradaxa® (dabigatran etexilate mesylate) Packets
  • Qfitlia™ (Fitusiran)
  • Siklos® (hydroxyurea)
  • Tryngolza® (Olezarsen)
  • Xromi® (hydroxyurea)


Effective with dates of service on or after April 1, 2026, the following medications will be Preferred:

  • Droxia® (hydroxyurea)
  • Eliquis® (apixaban) Sprinkle
  • Eliquis® (apixaban) TBS
  • Hemlibra® (Emicizumab-kxwh)
  • Otezla® (apremilast) XR
  • Redemplo® (Plozasiran)
  • Wegovy® (Semaglutide)
  • Xarelto® for Suspension


Note: The effective date of the policy is April 1, 2026. The  implementation of State policy by the KanCare Managed Care Organizations (MCOs) may vary from the date noted in the Kansas Medical Assistance Program (KMAP) bulletins. The KanCare Open Claims Resolution Log on the KMAP Bulletins page documents the MCO system status for policy implementation and any associated reprocessing completion dates once the policy is implemented.